Goodwill And Other Intangibles (Tables)

3 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of changes in the carrying amount of goodwill

Changes in the carrying amount of our goodwill for the three months ended March 31, 2017 were as follows (in thousands):

	Carrying Amount
	U.S. Generic Pharmaceuticals		U.S. Branded Pharmaceuticals		International Pharmaceuticals			Total
Goodwill as of December 31, 2016	$	3,531,301	$	1,009,248	$	188,846		$	4,729,395
Effect of currency translation on gross balance	—		—		10,448			10,448
Effect of currency translation on accumulated impairment	—		—		(6,914		)	(6,914		)
Goodwill impairment charges	—		—		(82,602		)	(82,602		)
Goodwill as of March 31, 2017	$	3,531,301	$	1,009,248	$	109,778		$	4,650,327

The carrying amount of goodwill at March 31, 2017 and December 31, 2016 is net of the following accumulated impairments:

	Accumulated Impairment
	U.S. Generic Pharmaceuticals		U.S. Branded Pharmaceuticals		International Pharmaceuticals		Total
Accumulated impairment losses as of December 31, 2016	$	2,342,549	$	675,380	$	408,280	$	3,426,209
Accumulated impairment losses as of March 31, 2017	$	2,342,549	$	675,380	$	497,796	$	3,515,725

Schedule of other intangible assets

The following is a summary of other intangible assets held by the Company at March 31, 2017 and December 31, 2016 (in thousands):

Cost basis:	Balance as of December 31, 2016			Acquisitions			Impairments (1)			Other (2)			Effect of Currency Translation (1)			Balance as of March 31, 2017
Indefinite-lived intangibles:
In-process research and development	$	1,123,581		$	—		$	(45,489	)	$	(128,600	)	$	209		$	949,701
Total indefinite-lived intangibles	$	1,123,581		$	—		$	(45,489	)	$	(128,600	)	$	209		$	949,701
Finite-lived intangibles:
Licenses (weighted average life of 12 years)	$	465,720		$	—		$	—		$	—		$	—		$	465,720
Tradenames (weighted average life of 12 years)	7,345			—			—			—			101			7,446
Developed technology (weighted average life of 11 years)	6,223,004			—			(73,417		)	128,600			13,745			6,291,932
Total finite-lived intangibles (weighted average life of 11 years)	$	6,696,069		$	—		$	(73,417	)	$	128,600		$	13,846		$	6,765,098
Total other intangibles	$	7,819,650		$	—		$	(118,906	)	$	—		$	14,055		$	7,714,799
Accumulated amortization:	Balance as of December 31, 2016			Amortization			Impairments			Other			Effect of Currency Translation			Balance as of March 31, 2017
Finite-lived intangibles:
Licenses	$	(341,600	)	$	(7,293	)	$	—		$	—		$	—		$	(348,893	)
Tradenames	(6,599		)	(20		)	—			—			(22		)	(6,641		)
Developed technology	(1,612,154		)	(255,821		)	—			—			(3,425		)	(1,871,400		)
Total other intangibles	$	(1,960,353	)	$	(263,134	)	$	—		$	—		$	(3,447	)	$	(2,226,934	)
Net other intangibles	$	5,859,297														$	5,487,865

__________

(1) Additional information on the changes in the total gross carrying amount of our other intangible assets is presented below (in thousands):

	Gross Carrying Amount
December 31, 2016	$	7,819,650
Impairment of certain U.S. Generic Pharmaceuticals intangible assets	(72,700		)
Impairment of certain International Pharmaceuticals intangible assets	(46,206		)
Effect of currency translation	14,055
March 31, 2017	$	7,714,799

(2) Includes reclassification adjustments of $128.6 million for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the three months ended March 31, 2017.

Schedule of changes in gross carrying amount of other intangible assets

Additional information on the changes in the total gross carrying amount of our other intangible assets is presented below (in thousands):

	Gross Carrying Amount
December 31, 2016	$	7,819,650
Impairment of certain U.S. Generic Pharmaceuticals intangible assets	(72,700		)
Impairment of certain International Pharmaceuticals intangible assets	(46,206		)
Effect of currency translation	14,055
March 31, 2017	$	7,714,799

Schedule of future amortization expense

Estimated amortization of intangibles for the five fiscal years subsequent to December 31, 2016 is as follows (in thousands):

2017	$	780,548
2018	$	579,733
2019	$	513,371
2020	$	482,111
2021	$	467,639